SKSongul Kucukcelebi

Songul Kucukcelebi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Songul Kucukcelebi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting

    by Songul Kucukcelebi, Aniek E. van Diepen, Judith de Vos-Geelen, Casper H. J. van Eijck, Nadine van Montfoort, Casper W. F. van Eijck

    Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and largely refractory to immune checkpoint inhibition because limited antigen-specific priming, myeloid suppression, dense desmoplasia, and abnormal vasculature enforce immune exclusion. CD40 links CD4+ T-cell help through CD40L/CD154 to antigen-presenting-cell (APC) licensing and CD8+ T-cell priming, making CD40 agonism a rational strategy to stimulate antitumor immunity in PDAC. CD40 is expressed on APCs and has also been reported on subsets of PDAC tumor cells, cancer-associated fibroblasts, and endothelial cells, indicating that CD40 agonists may affect immune activation, stromal/vascular remodeling, and context-dependent tumor-cell-intrinsic signaling. TRAF-dependent CD40 signaling activates canonical and non-canonical NF-kB, MAPK, and PI3K/AKT pathways, promoting APC maturation, IL-12-associated Th1 programming, macrophage repolarization, and matrix remodeling; tumor-intrinsic effects remain more variable, ranging from apoptotic to pro-survival programs. Clinically, CD40 agonists have shown pharmacodynamic immune engagement and manageable toxicity, mainly in combinations with chemotherapy, checkpoint inhibitors, and vaccine platforms, but efficacy remains inconsistent, and randomized validation is incomplete. Baseline CD40 expression has not reliably predicted benefit. Future development should prioritize spatially resolved tumor-immune profiling, longitudinal pharmacodynamic biomarkers, optimized sequencing, and agent-specific dosing strategies. This review integrates CD40 expression, signaling, and clinical evidence in PDAC to support more rational, biomarker-guided development of CD40-directed immunotherapy.

  • Open Access

    CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting

    by Songul Kucukcelebi, Aniek E. van Diepen, Judith de Vos-Geelen, Casper H.J. van Eijck, Nadine van Montfoort, Casper W.F. van Eijck

    Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and is largely refractory to immune checkpoint inhibition, reflecting limited antigen-specific priming, dominant myeloid suppression, dense desmoplasia, and abnormal vasculature that together enforce immune exclusion. CD40 is a central costimulatory receptor that links CD4⁺ T cell help (via CD40L/CD154) to antigen-presenting cell (APC) licensing and effective CD8⁺ T cell priming, positioning CD40 agonism as a rational strategy to enhance antitumor immunity in PDAC. In addition to robust expression on APC populations (DCs, macrophages, and B cells), CD40 has been reported on subsets of PDAC tumor cells and stromal compartments (including fibroblasts and endothelial cells), implying that CD40-directed therapies may engage multiple cellular nodes and influence both immune activation and microenvironmental remodeling. Mechanistically, CD40 signaling integrates TRAF-dependent pathways (canonical/non-canonical NF-κB, MAPK, and PI3K/AKT) that can promote APC maturation, IL-12-associated Th1 programming, macrophage repolarization, and matrix remodeling that may reduce physical barriers to immune infiltration; however, tumor-intrinsic CD40 signaling can be context-dependent and has been linked to divergent survival or apoptotic outcomes in different settings. Clinically, multiple CD40 agonists are in development, predominantly in combination regimens with chemotherapy, checkpoint blockade, and/or vaccine platforms, with evidence of pharmacodynamic immune engagement but variable efficacy and incomplete randomized validation. Baseline CD40 expression has not consistently predicted benefit, underscoring the need for spatially resolved profiling and on-treatment pharmacodynamic biomarkers to guide patient selection, sequencing, and regimen optimization. Ongoing studies and next-generation, tumor-localized agonist formats will define whether CD40 agonism can deliver consistent, durable clinical benefit in PDAC.

  • Open Access

    REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer

    by Songul Kucukcelebi, Freek R. van ‘T Land, Sjoerd H. van der Burg, Ferry A. L. M. Eskens, Marjolein Y. V. Homs, Marcella Willemsen, Anne Onrust-Van Schoonhoven, Nina E. M. Rozendaal, Amine Fellah, Disha Vadgama, et al.

    In pancreatic ductal adenocarcinoma (PDAC), the dense desmoplastic stroma and insufficient infiltrating T cells represent a significant barrier to effective immunotherapy. In this phase I, dose-escalation study, previously registered at the Dutch Trial Register and later on at ClinicalTrial (NCT05650918), we administer an autologous dendritic cell (DC) vaccine (MesoPher) with an agonistic CD40-specific antibody (mitazalimab) to metastatic PDAC patients (n = 16) after (m)FOLFIRINOX treatment. We included patients with WHO performance status 0-1 with accessible metastatic lesions, and excluded patients with history of previous immunotherapy or malignant ascites. Primary objectives include safety and tolerability. Immune modulation and clinical outcomes are monitored as secondary objectives. MesoPher (25 × 106 DCs) is co-administered with 300, 600, or 1200 μg/kg mitazalimab. MesoPher/mitazalimab therapy is safe and well-tolerated, and the primary endpoint is met. One transient dose-limiting toxicity (DLT) is observed (grade 3 fever). MesoPher/mitazalimab induces a systemic increase in activated and vaccine-specific T cell responses. In post-therapy tumor biopsies, increased T cell infiltration and decreased collagen deposition are observed. No objective radiological response is observed, but eight patients (50%) show stable disease after three administrations. In conclusion, MesoPher/mitazalimab combination therapy is safe and tolerable in patients with metastatic PDAC and enhances systemic immune activation and local immune responses. Future research should evaluate the efficacy of this promising approach as maintenance therapy shortly after completing chemotherapy.


  • Open Access

    Figure S1 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Supplementary Figure S1. Gating strategy of flow cytometry analyses on blood samples. Two panels were designed to investigate the presence and activation of peripheral T cells, DCs, and myeloid cells. The top-row gating strategy was applied in all panels.

  • Open Access

    Figure S3 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Supplementary Figure S3. Transcriptomic NanoString analysis for delta values (after mRNA counts – baseline mRNA counts). (A) t-SNE plot illustrates no apparent segregation of delta changes among 730 immune-related genes based on treatment response. (B) Boxplots displaying significant DE genes between stable and progressive disease patients upon rintatolimod treatment. The x-axis represents different genes, and the y-axis represents the log2 gene expression count.

  • Open Access

    Data from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Purpose:Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.Experimental Design:Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.Results:Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.Conclusions:This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

  • Open Access

    Supplementary Table S1 - S10 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Supplementary Table S1. Antibodies used for flow cytometry analyses. Supplementary Table S2. Selected marker genes to identify immune cell type in the transcriptomic NanoString analysis.Supplementary Table S3. Summary of sample inclusion in various immunoprofiling analyses.Supplementary Table S4. Treatment characteristics of the included PDAC patients (n = 30).Supplementary Table S5. Univariate Cox proportional hazards models for OS and PFS of the clinical covariates.Supplementary Table S6. Clinical and treatment characteristics of the PDAC patients included in the flow cytometry analysis.Supplementary Table S7. Pathway overrepresentation analyses of the transcriptomic NanoString analysis. Genes with significant overexpression (P < 0.01) in baseline samples compared to after 12 rintatolimod infusions are included.Supplementary Table S8. Univariate Cox proportional hazards models for OS and PFS of the NanoString immune cell counts.Supplementary Table S9. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients receiving ≤ and > median of 10 FOLFIRINOX cycles.Supplementary Table S10. Transcriptomic NanoString (A, B) and flowcytometry (C) immunoprofiling analysis comparing patients who did receive and did not receive SBRT.

  • Open Access

    Figure S3 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Supplementary Figure S3. Transcriptomic NanoString analysis for delta values (after mRNA counts – baseline mRNA counts). (A) t-SNE plot illustrates no apparent segregation of delta changes among 730 immune-related genes based on treatment response. (B) Boxplots displaying significant DE genes between stable and progressive disease patients upon rintatolimod treatment. The x-axis represents different genes, and the y-axis represents the log2 gene expression count.

  • Open Access

    Figure S2 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Supplementary Figure S2. Relative abundance of peripheral immune cells. (A-D) Boxplots illustrating the differences in immune cell scores between baseline and post-rintatolimod (A), between progressive disease and stable disease patients at baseline (B), between progressive disease and stable disease patients post-rintatolimod (C), and delta change between progressive disease and stable disease patients (D). The x-axis displays the different immune cell subsets, and the y-axis displays the immune cell score or delta immune cell score (upper right).

  • Open Access

    Data from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

    by Hassana el Haddaoui, Songul Kucukcelebi, Disha Vadgama, Amine Fellah, Dana A.M. Mustafa, Joachim G.J.V. Aerts, Casper H.J. van Eijck, Marcella Willemsen

    Purpose:Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.Experimental Design:Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.Results:Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.Conclusions:This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355